136 related articles for article (PubMed ID: 27356304)
1. Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation.
Zhang H; Ma K; Liu W; Yang F; Liu J; Zhou H
Gene; 2016 Oct; 591(1):80-84. PubMed ID: 27356304
[TBL] [Abstract][Full Text] [Related]
2. Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response.
Liu XL; Jia QJ; Wang LN; Liu ZM; Liu H; Duan XC; Lyu XM
Med Sci Monit; 2016 Jan; 22():310-5. PubMed ID: 26822491
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.
Tantray JA; Reddy KP; Jamil K; Kumar YS
Int J Cardiol; 2017 Feb; 229():113-118. PubMed ID: 27915083
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
5. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
[TBL] [Abstract][Full Text] [Related]
6. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
7. Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico.
Cedillo-Salazar FR; Martínez-Jacobo L; Pérez-Páramo YX; Cerda-Flores R; Martínez LE; Jaime-Pérez JC; Moreno-Treviño MG; Pérez-Rodríguez E; Bosques-Padilla FJ; Cedillo-Avila M; Cedillo-Avila MA; Zamudio-Osuna M
Arch Cardiol Mex; 2019; 89(4):324-329. PubMed ID: 31834317
[TBL] [Abstract][Full Text] [Related]
8. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
9. Impact of
Wang D; Yong L; Zhang Q; Chen H
Pharmacogenomics; 2022 Nov; 23(16):903-911. PubMed ID: 36222113
[No Abstract] [Full Text] [Related]
10. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
12. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang.
Kamali X; Wulasihan M; Yang YC; Lu WH; Liu ZQ; He PY
Lipids Health Dis; 2013 Oct; 12():149. PubMed ID: 24148610
[TBL] [Abstract][Full Text] [Related]
13. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
14. Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children.
Favela-Mendoza AF; Martínez-Cortes G; Romero-Prado MM; Romero-Tejeda EM; Islas-Carbajal MC; Sosa-Macias M; Lares-Asseff I; Rangel-Villalobos H
J Clin Pharm Ther; 2018 Oct; 43(5):656-663. PubMed ID: 29733119
[TBL] [Abstract][Full Text] [Related]
15. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.
Li Y; Yang H; Zou X; Xiong L; Li Z; Luo J; Zhao B; Liu W; Du X
Med Sci Monit; 2014 Nov; 20():2213-8. PubMed ID: 25381554
[TBL] [Abstract][Full Text] [Related]
18. VKORC1 -1639G/A and 1173 C/T Genetic Polymorphisms Influence Individual Differences in Warfarin Maintenance Dose.
Li Y; Zhu J; Ding J
Genet Test Mol Biomarkers; 2015 Sep; 19(9):488-93. PubMed ID: 26167638
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
Chang M; Söderberg MM; Scordo MG; Tybring G; Dahl ML
Eur J Clin Pharmacol; 2015 Apr; 71(4):433-9. PubMed ID: 25652102
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
